

# Michael H Weisman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/271841/publications.pdf>

Version: 2024-02-01

201  
papers

20,530  
citations

44444

50  
h-index

11608

140  
g-index

204  
all docs

204  
docs citations

204  
times ranked

18318  
citing authors

#	ARTICLE	IF	CITATIONS
1	Correspondence on “Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry”™. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e138-e138.	0.5	4
2	Incidence of Ankylosing Spondylitis Among Male and Female United States Army Personnel. <i>Arthritis Care and Research</i> , 2023, 75, 332-339.	1.5	7
3	Identifying trajectories of radiographic spinal disease in ankylosing spondylitis: a 15-year follow-up study of the PSOAS cohort. <i>Rheumatology</i> , 2022, 61, 2079-2087.	0.9	8
4	The Interplay Between COVID-19 and Spondyloarthritis or Its Treatment. <i>Journal of Rheumatology</i> , 2022, 49, 225-229.	1.0	9
5	Risk Factors for Spinal Structural Damage in a Chinese Cohort With Ankylosing Spondylitis. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e118-e124.	0.5	4
6	High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. <i>Rheumatology</i> , 2022, 61, 4335-4343.	0.9	6
7	Spondyloarthritis in inflammatory bowel disease cohorts: systematic literature review and critical appraisal of study designs. <i>RMD Open</i> , 2022, 8, e001777.	1.8	11
8	Does Gender Impact a Diagnosis of Ankylosing Spondylitis?. <i>ACR Open Rheumatology</i> , 2022, 4, 540-546.	0.9	3
9	A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1179-1191.	1.9	7
10	Chronic inflammatory back pain commencing late in life: a neglected concept. <i>Internal Medicine Journal</i> , 2022, 52, 485-487.	0.5	0
11	The Need for SPACE to Plan the Future for Spondyloarthritis. <i>Journal of Rheumatology</i> , 2022, 49, 341-342.	1.0	1
12	The Effect of HLA-B27 on Susceptibility and Severity of COVID-19. <i>Journal of Rheumatology</i> , 2021, 48, 621-622.	1.0	19
13	Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 154-161.	0.5	21
14	Foreword. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, xi-xii.	0.8	0
15	A Panel of Biomarkers Associates With Increased Risk for Cardiovascular Events in Women With Systemic Lupus Erythematosus. <i>ACR Open Rheumatology</i> , 2021, 3, 209-220.	0.9	14
16	Pulse dose steroid experience among hospitalized patients with systemic lupus erythematosus: a single-center feasibility study. <i>Clinical Rheumatology</i> , 2021, 40, 1317-1320.	1.0	0
17	Association of Lipid Mediators With Development of Future Incident Inflammatory Arthritis in an Anti-“Citruillinated Protein Antibody”-Positive Population. <i>Arthritis and Rheumatology</i> , 2021, 73, 955-962.	2.9	10
18	Low levels of anti-cyclic citruillinated peptide (CCP) 3.1 associated with diseases other than rheumatoid arthritis. <i>Medicine (United States)</i> , 2021, 100, e25558.	0.4	2

#	ARTICLE	IF	CITATIONS
19	The arthritis connection to inflammatory bowel disease (IBD): why has it taken so long to understand it?. <i>RMD Open</i> , 2021, 7, e001558.	1.8	23
20	Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1168-1174.	0.5	49
21	Pain in Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, xi-xii.	0.8	0
22	Repeated Spinal Mobility Measures and Their Association With Radiographic Damage in Ankylosing Spondylitis. <i>ACR Open Rheumatology</i> , 2021, 3, 413-421.	0.9	0
23	HLA-B27 is associated with reduced disease activity in axial spondyloarthritis. <i>Scientific Reports</i> , 2021, 11, 12331.	1.6	7
24	Does hydroxychloroquine improve patient reported outcomes in patients with lupus?. <i>Lupus</i> , 2021, 30, 1790-1798.	0.8	1
25	Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. <i>Lupus Science and Medicine</i> , 2021, 8, e000522.	1.1	5
26	Prevalence of sacroiliitis among patients referred for hip MR arthrography. <i>Skeletal Radiology</i> , 2021, , 1.	1.2	3
27	Lupus. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, xiii-xiv.	0.8	0
28	Evaluating associations of joint swelling, joint stiffness and joint pain with physical activity in first-degree relatives of patients with rheumatoid arthritis: Studies of the Aetiology of Rheumatoid Arthritis (SERA), a prospective cohort study. <i>BMJ Open</i> , 2021, 11, e050883.	0.8	2
29	The Association of Tumor Necrosis Factor Inhibitor Use With Incident Hypertension in Ankylosing Spondylitis: Data From the PSOAS Cohort. <i>Journal of Rheumatology</i> , 2021, , jrheum.210332.	1.0	3
30	Five-Year Follow-Up of Coronary Microvascular Dysfunction and Coronary Artery Disease in Systemic Lupus Erythematosus: Results From a Community-Based Lupus Cohort. <i>Arthritis Care and Research</i> , 2020, 72, 882-887.	1.5	21
31	American Indians Have a Higher Risk of Sjögren's Syndrome and More Disease Activity Than European Americans and African Americans. <i>Arthritis Care and Research</i> , 2020, 72, 1049-1056.	1.5	14
32	A latent class based imputation method under Bayesian quantile regression framework using asymmetric Laplace distribution for longitudinal medication usage data with intermittent missing values. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 160-177.	0.4	2
33	Nonsteroidal Antiinflammatory Drug Use and Association With Incident Hypertension in Ankylosing Spondylitis. <i>Arthritis Care and Research</i> , 2020, 72, 1645-1652.	1.5	21
34	Perceived Stress and Inflammatory Arthritis: A Prospective Investigation in the Studies of the Etiologies of Rheumatoid Arthritis Cohort. <i>Arthritis Care and Research</i> , 2020, 72, 1766-1771.	1.5	21
35	Education and Professional Development in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, xiii-xiv.	0.8	0
36	A review of non-immune mediated kidney disease in systemic lupus erythematosus: A hypothetical model of putative risk factors. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 463-472.	1.6	6

#	ARTICLE	IF	CITATIONS
37	Examining Treatment Decision-Making Among Patients With Axial Spondyloarthritis: Insights From a Conjoint Analysis Survey. <i>ACR Open Rheumatology</i> , 2020, 2, 391-400.	0.9	12
38	Coping profiles and health outcomes among individuals with systemic sclerosis: A latent profile analysis approach. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 231-236.	1.0	2
39	Spondyloarthritis evolution: what is in your history?. <i>Current Opinion in Rheumatology</i> , 2020, 32, 321-329.	2.0	10
40	Biologics, spondylitis and COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1663-1665.	0.5	25
41	Longitudinal associations between depressive symptoms and clinical factors in ankylosing spondylitis patients: analysis from an observational cohort. <i>Rheumatology International</i> , 2020, 40, 1053-1061.	1.5	8
42	The road to rheumatoid arthritis prevention: challenges and opportunities. <i>Clinical Rheumatology</i> , 2020, 39, 1379-1381.	1.0	6
43	The changing profile of ankylosing spondylitis in the biologic era. <i>Clinical Rheumatology</i> , 2020, 39, 2641-2651.	1.0	3
44	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1243-1249.	0.5	93
45	Foreword. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, xi.	0.8	0
46	Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. <i>Arthritis and Rheumatology</i> , 2020, 72, 1067-1071.	2.9	13
47	Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 193-201.	0.5	59
48	Population-based estimates of humoral autoimmunity from the U.S. National Health and Nutrition Examination Surveys, 1960-2014. <i>PLoS ONE</i> , 2020, 15, e0226516.	1.1	15
49	Spondyloarthritis: The Changing Landscape—Are We There Yet?. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, xiii-xiv.	0.8	2
50	Insights From Twitter Conversations on Lupus and Reproductive Health: Protocol for a Content Analysis. <i>JMIR Research Protocols</i> , 2020, 9, e15623.	0.5	6
51	Chronic back pain in first-degree relatives (FDRs) of patients with ankylosing spondylitis: predictive value of HLA-B27 and persistence of inflammatory back pain over time. <i>RMD Open</i> , 2020, 6, e001418.	1.8	3
52	Foreword. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, xiii-xiv.	0.8	0
53	Prevalence and Associations of Avascular Necrosis of the Hip in a Large Well-characterized Cohort of Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 45-49.	0.5	8
54	Patient Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights From a Large-Scale Survey of Social Media Platforms. <i>Arthritis Care and Research</i> , 2019, 71, 323-330.	1.5	25

#	ARTICLE	IF	CITATIONS
55	Technology and Big Data in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, xiii-xiv.	0.8	0
56	Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1235-1241.	0.5	64
57	Anticyclic Citrullinated Peptide Antibodies 3.1 and Anti-CCP-IgA Are Associated with Increasing Age in Individuals Without Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 1556-1559.	1.0	12
58	Hydroxychloroquine – How Much Is Too Much?. <i>Journal of Rheumatology</i> , 2019, 46, 340-342.	1.0	6
59	Cauda Equina Syndrome in Ankylosing Spondylitis: Challenges in Diagnosis, Management, and Pathogenesis. <i>Journal of Rheumatology</i> , 2019, 46, 1582-1588.	1.0	15
60	Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients. <i>EBioMedicine</i> , 2019, 42, 76-85.	2.7	18
61	New-onset non-infectious pulmonary manifestations among patients with systemic lupus erythematosus in Sweden. <i>Arthritis Research and Therapy</i> , 2019, 21, 48.	1.6	9
62	THU0358 – DEVELOPMENT OF A SET OF ASAS QUALITY STANDARDS FOR ADULTS WITH AXIAL SPONDYLOARTHRITIS. , 2019, , .		0
63	Drivers of Satisfaction With Care for Patients With Lupus. <i>ACR Open Rheumatology</i> , 2019, 1, 649-656.	0.9	9
64	Controversies in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, xiii-xiv.	0.8	0
65	Treat to Target in Rheumatic Diseases: Rationale and Results. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, ix-x.	0.8	0
66	Clinical features related to statin-associated muscle symptoms. <i>Muscle and Nerve</i> , 2019, 59, 537-543.	1.0	12
67	Best Practices and Challenges to the Practice of Rheumatologists. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, xiii-xiv.	0.8	0
68	HLA class I and II alleles in susceptibility to ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 66-73.	0.5	52
69	Sex Differences in Quality of Life in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019, 71, 1647-1652.	1.5	21
70	A promising approach to targeting type 1 IFN in systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2019, 129, 958-961.	3.9	18
71	Interstitial lung abnormalities in patients with early rheumatoid arthritis: A pilot study evaluating prevalence and progression. <i>European Journal of Rheumatology</i> , 2019, 6, 193-198.	1.3	22
72	Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2018, 5, e000247.	1.1	16

#	ARTICLE	IF	CITATIONS
73	A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. <i>Human Molecular Genetics</i> , 2018, 27, 2392-2404.	1.4	34
74	Causes and Predictors of Early Hospital Readmission in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018, 45, 929-933.	1.0	9
75	US National Health and Nutrition Examination Survey Arthritis Initiatives, Methodologies and Data. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, 215-265.	0.8	15
76	Digestive and Hepatic Aspects of the Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, xiii-xiv.	0.8	0
77	Antibody Responses to Citrullinated and Noncitrullinated Antigens in the Sputum of Subjects With Rheumatoid Arthritis and Subjects at Risk for Development of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 516-527.	2.9	51
78	The Brave New World of Rheumatic Disease Research Today. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, xiii.	0.8	1
79	Role of psychosocial reserve capacity in anxiety and depression in patients with systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 850-858.	0.9	14
80	Opioid Analgesic Use in Patients with Ankylosing Spondylitis: An Analysis of the Prospective Study of Outcomes in an Ankylosing Spondylitis Cohort. <i>Journal of Rheumatology</i> , 2018, 45, 188-194.	1.0	20
81	Renal Involvement in Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, xi.	0.8	0
82	Etiology unknown: Qualitative analysis of patient attributions of causality in scleroderma. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 182-188.	1.0	0
83	Rheumatic Diseases in Older Adults. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, xi-xii.	0.8	0
84	A multiple imputation method based on weighted quantile regression models for longitudinal censored biomarker data with missing values at early visits. <i>BMC Medical Research Methodology</i> , 2018, 18, 8.	1.4	11
85	Harmonization, data management, and statistical issues related to prospective multicenter studies in Ankylosing spondylitis (AS): Experience from the Prospective Study Of Ankylosing Spondylitis (PSOAS) cohort. <i>Contemporary Clinical Trials Communications</i> , 2018, 11, 127-135.	0.5	14
86	Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus. <i>Molecular Medicine</i> , 2018, 24, 24.	1.9	12
87	Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. <i>Human Molecular Genetics</i> , 2018, 27, 3813-3824.	1.4	43
88	Trans-Ethnic Mapping of BANK1 Identifies Two Independent SLE-Risk Linkage Groups Enriched for Co-Transcriptional Splicing Marks. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2331.	1.8	12
89	IL-16/miR-125a axis controls neutrophil recruitment in pristane-induced lung inflammation. <i>JCI Insight</i> , 2018, 3, .	2.3	34
90	Trends in Functional Disability and Determinants of Clinically Meaningful Change Over Time in Hispanic Patients With Rheumatoid Arthritis in the US. <i>Arthritis Care and Research</i> , 2017, 69, 294-298.	1.5	15

#	ARTICLE	IF	CITATIONS
91	A Randomized, Double-blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 846-853.	2.9	131
92	A Randomized, Double-blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 837-845.	2.9	271
93	Omega-3 fatty acids are associated with a lower prevalence of autoantibodies in shared epitope-positive subjects at risk for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 147-152.	0.5	72
94	Anti-Citrullinated Protein Antibodies Are Associated With Neutrophil Extracellular Traps in the Sputum in Relatives of Rheumatoid Arthritis Patients. <i>Arthritis and Rheumatology</i> , 2017, 69, 1165-1175.	2.9	93
95	Editorial: The Effect of Ethnicity on Cardiovascular Outcomes in Systemic Lupus Erythematosus Is Perhaps Not a Paradox. <i>Arthritis and Rheumatology</i> , 2017, 69, 1707-1709.	2.9	1
96	Prevalence of resting-ECG abnormalities in systemic lupus erythematosus: a single-center experience. <i>Clinical Rheumatology</i> , 2017, 36, 1311-1316.	1.0	27
97	Reproductive Health. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, xi-xii.	0.8	0
98	Combined role of vitamin D status and <i>CYP24A1</i> in the transition to systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 153-158.	0.5	40
99	MicroRNA-302d targets IRF9 to regulate the IFN-induced gene expression in SLE. <i>Journal of Autoimmunity</i> , 2017, 79, 105-111.	3.0	66
100	Relationship between the gut and the spine: a pilot study of first-degree relatives of patients with ankylosing spondylitis. <i>RMD Open</i> , 2017, 3, e000437.	1.8	1
101	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017, 8, 16021.	5.8	314
102	Brief Report: Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2017, 69, 2187-2192.	2.9	35
103	Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups. <i>Clinical Rheumatology</i> , 2017, 36, 2359-2364.	1.0	35
104	Psychological Factors that Link Socioeconomic Status to Depression/Anxiety in Patients with Systemic Lupus Erythematosus. <i>Journal of Clinical Psychology in Medical Settings</i> , 2017, 24, 302-315.	0.8	25
105	Association of Antibodies to Citrullinated Protein Antigens with Blood Pressure in First-Degree Relatives of Rheumatoid Arthritis Patients: The Studies of the Etiology of Rheumatoid Arthritis. <i>American Journal of Nephrology</i> , 2017, 46, 481-487.	1.4	4
106	Strong viral associations with SLE among Filipinos. <i>Lupus Science and Medicine</i> , 2017, 4, e000214.	1.1	24
107	Neurologic Manifestations of Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, xi.	0.8	0
108	Cadherin-11 Is a Cell Surface Marker Up-Regulated in Activated Pancreatic Stellate Cells and Is Involved in Pancreatic Cancer Cell Migration. <i>American Journal of Pathology</i> , 2017, 187, 146-155.	1.9	38

#	ARTICLE	IF	CITATIONS
109	Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features. <i>Arthritis and Rheumatology</i> , 2017, 69, 630-642.	2.9	56
110	Infection and Malignancy in Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, xi-xii.	0.8	0
111	Effect of Tobacco Smoking on The Clinical, Histopathological, and Serological Manifestations of Sjögren's Syndrome. <i>PLoS ONE</i> , 2017, 12, e0170249.	1.1	25
112	Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. <i>PLoS Genetics</i> , 2017, 13, e1006820.	1.5	60
113	A Case of Henoch-Schonlein Purpura Associated with Rotavirus Infection in an Elderly Asian Male and Review of the Literature. <i>American Journal of Case Reports</i> , 2017, 18, 136-142.	0.3	8
114	Genomics in Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, xiii-xiv.	0.8	0
115	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016, 68, 1290-1300.	2.9	114
116	Review: Enthesitis: New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment. <i>Arthritis and Rheumatology</i> , 2016, 68, 312-322.	2.9	128
117	Infection, malignancy, switching, biosimilars, antibody formation, drug survival and withdrawal, and dose reduction. <i>Current Opinion in Rheumatology</i> , 2016, 28, 303-309.	2.0	3
118	Associations of Smoking and Age With Inflammatory Joint Signs Among Unaffected First-Degree Relatives of Rheumatoid Arthritis Patients: Results From Studies of the Etiology of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1828-1838.	2.9	46
119	Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. <i>Clinical Immunology</i> , 2016, 168, 25-29.	1.4	68
120	Sjogren's Disease. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, xi-xii.	0.8	1
121	Imaging in Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, xiii.	0.8	0
122	Patient-Reported Outcomes in Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, xiii-xiv.	0.8	1
123	Brief Report: Patients With Primary Sjögren's Syndrome Who Are Positive for Autoantibodies to Tripartite Motif-Containing Protein 38 Show Greater Disease Severity. <i>Arthritis and Rheumatology</i> , 2016, 68, 724-729.	2.9	22
124	Previous diagnosis of Sjögren's Syndrome as rheumatoid arthritis or systemic lupus erythematosus. <i>Rheumatology</i> , 2016, 55, 1195-1201.	0.9	42
125	Corticosteroids. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, xiii.	0.8	2
126	Lower omega-3 fatty acids are associated with the presence of anti-cyclic citrullinated peptide autoantibodies in a population at risk for future rheumatoid arthritis: a nested case-control study. <i>Rheumatology</i> , 2016, 55, 367-376.	0.9	52

#	ARTICLE	IF	CITATIONS
127	Multidimensional Model of Disability and Role Functioning in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2015, 67, 1686-1692.	1.5	4
128	Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. <i>Nature Communications</i> , 2015, 6, 7146.	5.8	220
129	Chest pain in lupus patients: the emergency department experience. <i>Clinical Rheumatology</i> , 2015, 34, 1969-1973.	1.0	2
130	Monoclonal Antibodies, Systemic Lupus Erythematosus, and Pregnancy: Insights from an Open-label Study. <i>Journal of Rheumatology</i> , 2015, 42, 728-730.	1.0	8
131	ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1627-1629.	0.5	86
132	Systemic Sclerosis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, xiii.	0.8	1
133	Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, xi.	0.8	0
134	Treatment of systemic lupus erythematosus patients with the BAFF antagonist eceptibody blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. <i>Arthritis Research and Therapy</i> , 2015, 17, 215.	1.6	48
135	Prevalence of Chronic Axial Pain, Inflammatory Back Pain, and Spondyloarthritis in Diagnosed Psoriasis. <i>Arthritis Care and Research</i> , 2015, 67, 829-835.	1.5	22
136	Foreword. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, xi.	0.8	0
137	The role of methotrexate in psoriatic arthritis: what is the evidence?. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S94-7.	0.4	9
138	The Effect of Riloncept versus Placebo on Health-Related Quality of Life in Patients with Poorly Controlled Familial Mediterranean Fever. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	25
139	Gout and Crystal Arthropathies. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, xiii.	0.8	0
140	A Panel of Biomarkers Is Associated With Increased Risk of the Presence and Progression of Atherosclerosis in Women With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2014, 66, 130-139.	2.9	103
141	New Population-Based Reference Values for Spinal Mobility Measures Based on the 2009-2010 National Health and Nutrition Examination Survey. <i>Arthritis and Rheumatology</i> , 2014, 66, 2628-2637.	2.9	13
142	MICA, a gene contributing strong susceptibility to ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1552-1557.	0.5	47
143	Foreword. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, xi.	0.8	0
144	Foreword. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, xiii.	0.8	1

#	ARTICLE	IF	CITATIONS
145	The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administration's Comments and Concerns. <i>Arthritis and Rheumatology</i> , 2014, 66, 2649-2656.	2.9	81
146	Spine fractures in ankylosing spondylitis: A case report and review of imaging as well as predisposing factors to falls and fractures. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 20-24.	1.6	14
147	The Impact of Tumor Necrosis Factor Inhibitors on Radiographic Progression in Ankylosing Spondylitis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2645-2654.	6.7	391
148	Performance of Anti-Cyclic Citrullinated Peptide Assays Differs in Subjects at Increased Risk of Rheumatoid Arthritis and Subjects With Established Disease. <i>Arthritis and Rheumatism</i> , 2013, 65, 2243-2252.	6.7	64
149	Foreword. <i>Rheumatic Disease Clinics of North America</i> , 2013, 39, xv.	0.8	0
150	Foreword. <i>Rheumatic Disease Clinics of North America</i> , 2013, 39, ix.	0.8	0
151	Foreword. <i>Rheumatic Disease Clinics of North America</i> , 2013, 39, xiii.	0.8	0
152	The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009-10. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 369-373.	0.5	79
153	Sputum Autoantibodies in Patients With Established Rheumatoid Arthritis and Subjects at Risk of Future Clinically Apparent Disease. <i>Arthritis and Rheumatism</i> , 2013, 65, 2545-2554.	6.7	160
154	Microvascular Angina: An Underappreciated Cause of SLE Chest Pain. <i>Journal of Rheumatology</i> , 2013, 40, 746-747.	1.0	10
155	Functional Limitations Due to Axial and Peripheral Joint Impairments in Patients With Ankylosing Spondylitis: Are Focused Measures More Informative?. <i>Arthritis Care and Research</i> , 2013, 65, 607-614.	1.5	9
156	The Epidemiology of Back Pain, Axial Spondyloarthritis and HLA-B27 in the United States. <i>American Journal of the Medical Sciences</i> , 2013, 345, 431-436.	0.4	149
157	Lung abnormalities in subjects with elevations of rheumatoid arthritis-related autoantibodies without arthritis by examination and imaging suggest the lung is an early and perhaps initiating site of inflammation in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A25.1-A25.	0.5	5
158	Foreword. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, ix-x.	0.8	0
159	Inflammatory Back Pain. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 501-512.	0.8	36
160	Foreword. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, xiii-xv.	0.8	0
161	Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. <i>Arthritis Research and Therapy</i> , 2012, 14, R261.	1.6	44
162	Prevalence of axial spondylarthritis in the United States: Estimates from a cross-sectional survey. <i>Arthritis Care and Research</i> , 2012, 64, 905-910.	1.5	183

#	ARTICLE	IF	CITATIONS
163	Brief Report: Airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: Early injury or initiating site of autoimmunity?. <i>Arthritis and Rheumatism</i> , 2012, 64, 1756-1761.	6.7	213
164	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
165	Myocardial Ischemia in the Absence of Obstructive Coronary Artery Disease in Systemic Lupus Erythematosus. <i>JACC: Cardiovascular Imaging</i> , 2011, 4, 27-33.	2.3	138
166	High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1619-1624.	0.5	128
167	Development and validation of a case ascertainment tool for ankylosing spondylitis. <i>Arthritis Care and Research</i> , 2010, 62, 19-27.	1.5	23
168	Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. <i>Nature Genetics</i> , 2010, 42, 123-127.	9.4	573
169	Current Controversies in Spondyloarthritis: SPARTAN. <i>Journal of Rheumatology</i> , 2010, 37, 2617-2623.	1.0	11
170	Psychological Correlates of Self-reported Disease Activity in Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2010, 37, 829-834.	1.0	36
171	Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 60, 2428-2437.	6.7	178
172	A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA. <i>Arthritis and Rheumatism</i> , 2009, 61, 1735-1742.	6.7	129
173	Psychological correlates of self-reported functional limitation in patients with ankylosing spondylitis. <i>Arthritis Research and Therapy</i> , 2009, 11, R182.	1.6	51
174	Cost-Effectiveness of Sequential Therapy with Tumor Necrosis Factor Antagonists in Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 16-26.	1.0	38
175	Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2008, 59, 822-832.	6.7	72
176	Do all drugs and treatments for rheumatoid arthritis have the same efficacy?. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 298-299.	3.2	2
177	Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 633-638.	0.5	225
178	A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. <i>Rheumatology</i> , 2007, 46, 1122-1125.	0.9	57
179	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. <i>Nature Genetics</i> , 2007, 39, 1329-1337.	9.4	1,298
180	Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 607-612.	6.7	148

#	ARTICLE	IF	CITATIONS
181	Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2006, 33, 2162-6.	1.0	71
182	Chronic Inflammatory Demyelinating Polyneuropathy in Patients with Systemic Lupus Erythematosus: Prognosis and Outcome. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 175-184.	1.6	62
183	Progress toward the cure of rheumatoid arthritis? The best study. <i>Arthritis and Rheumatism</i> , 2005, 52, 3326-3332.	6.7	24
184	Relationships of Positive and Negative Affect to Coping and Functional Outcomes in Systemic Sclerosis. <i>Cognitive Therapy and Research</i> , 2004, 28, 593-610.	1.2	14
185	Development and validation of Cedars-Sinai Health-Related Quality of Life in Rheumatoid Arthritis (CSHQ-RA) short form instrument. <i>Arthritis and Rheumatism</i> , 2004, 51, 358-364.	6.7	8
186	Adalimumab, a fully human anti-tumor necrosis factor $\alpha$ monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. <i>Arthritis and Rheumatism</i> , 2003, 48, 35-45.	6.7	1,612
187	Development of a new instrument for rheumatoid arthritis: The Cedars-Sinai Health-Related Quality of Life instrument (CSHQ-RA). <i>Arthritis and Rheumatism</i> , 2003, 49, 78-84.	6.7	9
188	Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study. <i>Clinical Therapeutics</i> , 2003, 25, 1700-1721.	1.1	279
189	What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. <i>Journal of rheumatology Supplement</i> , The, 2002, 65, 33-8.	2.2	65
190	Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2000, 343, 1594-1602.	13.9	2,910
191	Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: A randomized, double-blind six-week trial with eighteen-week extension. <i>Arthritis and Rheumatism</i> , 1999, 42, 357-365.	6.7	78
192	High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial. <i>Arthritis and Rheumatism</i> , 1999, 42, 1194-1203.	6.7	312
193	Correlates of the disability index of the health assessment questionnaire: A measure of functional impairment in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1999, 42, 2372-2380.	6.7	96
194	Infliximab (chimeric anti-tumour necrosis factor $\alpha$ monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. <i>Lancet</i> , The, 1999, 354, 1932-1939.	6.3	2,266
195	Quality-adjusted life years lost to arthritis: Effects of gender, race, and social class. <i>Arthritis and Rheumatism</i> , 1996, 9, 473-482.	6.7	48
196	Primary lymphoma of the calcaneus. <i>Skeletal Radiology</i> , 1996, 25, 775-778.	1.2	18
197	Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative study. <i>Arthritis and Rheumatism</i> , 1996, 39, 2013-2020.	6.7	410
198	Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. <i>Arthritis and Rheumatism</i> , 1992, 35, 259-269.	6.7	139

#	ARTICLE	IF	CITATIONS
199	Reversible cause of back pain and sciatica in rheumatoid arthritis: An apophyseal joint cyst. <i>Arthritis and Rheumatism</i> , 1986, 29, 431-435.	6.7	31
200	Methotrexate pharmacokinetics after intraarticular injection in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1980, 23, 119-122.	6.7	73
201	Manure shoveler's hip: A previously unrecognized syndrome. <i>Arthritis and Rheumatism</i> , 1979, 22, 940-941.	6.7	3